ReSeqTB Data Sharing Platform Q4-2015 Update
Provide a one-stop data source for clinically relevant genotypic and phenotypic information on Mycobacterium tuberculosis (Mtb). This data, reviewed, validated, and accessible in one place, will support the development of new tests which can rapidly inform appropriate therapy for TB patients.
- Serve as a single repository for the compilation, curation and validation of existing and newly created data on TB drug resistance correlations.
- Implement an extensive database design to ensure quality and security of information, proven technical developer expertise, and meet all relevant legal, patient data privacy, and intellectual property standards.
4Q, 2015 Progress:
- ReSeqTB successfully launched the first release of the “early adopter” ReSeqTB Data Platform version on October 30, 2015.
- Access to the platform is only available to individuals or organizations that have contributed data or who have signed a CPTR RDST consortium membership agreement. Expanded access will be offered in the future.
- The ReSeqTB input expert committee developed a unified sequencing pipeline through a consensus process. It was validated using well characterized data sets. The team is developing a manuscript to detail the process and outline the pipeline thresholds.
- As of December 31, 2015, 1525 isolates are available in ReSeqTB .
- 393 isolates identified as resistant, 276 isolates identified as MDR resistant and 740 identified as drug susceptible.
- The ReSeqTB platform user base continued to grow through December.
- Fifteen total users including eight research users.
- Web access traffic grew to roughly 50 accesses per day from 6 countries.
- ReSeqTB has identified an initial list of high confidence mutations based on a literature search performed by FIND and the NDWG. These mutations will be verified by the incoming data and expanded as more polymorphisms are detected and vetted through the validation process.
- The ReSeqTB team recruited a consulting statistician to help identify a statistically valid method to identify polymorphisms associated with drug resistance.
- The Working Group presented the ReSeqTB data platform in two different sessions at the 2015 Annual Union meeting in Cape Town. Both presentations were well received.
- The ReSeqTB team held an expert face-face meeting in Cape Town to discuss process improvements for classifying and validating MTB mutations according to their predicted association with phenotypic drug resistance.